検索
Emergent BioSolutions Inc
EBSウォッチリストに追加
8.130USD
+0.190+2.39%
終値 05/18, 16:00（ET）15分遅れの株価
421.13M時価総額
損失額直近12ヶ月PER
詳細情報 Emergent BioSolutions Inc 企業名
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Emergent BioSolutions Incの企業情報
企業コードEBS
会社名Emergent BioSolutions Inc
上場日Nov 15, 2006
最高経営責任者「CEO」Papa (Joseph C)
従業員数900
証券種類Ordinary Share
決算期末Nov 15
本社所在地300 Professional Dr
都市GAITHERSBURG
証券取引所NASDAQ OMX NASDAQ Basic NYSE
国United States of America
郵便番号20879
電話番号12406313200
ウェブサイトhttps://emergentbiosolutions.com/
企業コードEBS
上場日Nov 15, 2006
最高経営責任者「CEO」Papa (Joseph C)
Emergent BioSolutions Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
271.92K
+59.83%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
155.93K
+64.20%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
146.77K
+68.21%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
116.59K
+85.86%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
114.67K
+22.10%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
89.36K
+28.36%
Mr. Marvin L. White
Mr. Marvin L. White
Independent Director
Independent Director
79.44K
+31.90%
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
59.03K
+16.71%
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
304.82K
+61.58%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
271.92K
+59.83%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
165.29K
+63.09%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
155.93K
+64.20%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
146.77K
+68.21%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
116.59K
+85.86%
収益内訳
通貨: USD更新時刻: Mon, Apr 6
通貨: USD更新時刻: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Commercial Product sales
223.30M
30.06%
MCM Product sales
156.50M
21.07%
Contracts and grants
36.70M
4.94%
Bioservices
23.40M
3.15%
地域別USD
会社名
収益
比率
Non-U.S Government
403.20M
54.27%
U.S.Government
36.70M
4.94%
事業別
地域別
事業別USD
会社名
収益
比率
Commercial Product sales
223.30M
30.06%
MCM Product sales
156.50M
21.07%
Contracts and grants
36.70M
4.94%
Bioservices
23.40M
3.15%
株主
更新時刻: Sun, May 10
更新時刻: Sun, May 10
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
7.60%
Dimensional Fund Advisors, L.P.
5.34%
State Street Investment Management (US)
5.23%
American Century Investment Management, Inc.
4.73%
Vanguard Capital Management, LLC
4.38%
他の
72.72%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
7.60%
Dimensional Fund Advisors, L.P.
5.34%
State Street Investment Management (US)
5.23%
American Century Investment Management, Inc.
4.73%
Vanguard Capital Management, LLC
4.38%
他の
72.72%
種類
株主統計
比率
Investment Advisor
37.35%
Investment Advisor/Hedge Fund
31.07%
Hedge Fund
8.77%
Research Firm
3.93%
Individual Investor
3.86%
Pension Fund
1.01%
Bank and Trust
0.36%
Family Office
0.06%
Insurance Company
0.02%
他の
13.55%
機関投資家保有株
更新時刻: Wed, Apr 1
更新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株式数
比率
変動額
2026Q1
412
42.30M
81.98%
-3.37M
2025Q4
378
39.86M
83.14%
+128.30K
2025Q3
417
39.73M
84.87%
+2.04M
2025Q2
439
37.58M
87.40%
+1.14M
2025Q1
454
36.44M
84.55%
-9.64M
2024Q4
461
35.04M
82.31%
+2.84M
2024Q3
467
32.21M
81.37%
+1.29M
2024Q2
485
30.86M
99.60%
-5.54M
2024Q1
494
36.44M
103.37%
-17.72M
2023Q4
512
41.89M
103.68%
-1.06M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
3.92M
7.6%
+17.75K
+0.45%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
2.25M
4.36%
+112.27K
+5.25%
Dec 31, 2025
State Street Investment Management (US)
2.70M
5.22%
+250.62K
+10.25%
Dec 31, 2025
American Century Investment Management, Inc.
2.44M
4.72%
+57.06K
+2.40%
Dec 31, 2025
Charles Schwab Investment Management, Inc.
1.62M
3.13%
+237.15K
+17.16%
Dec 31, 2025
Palisade Capital Management, LLC
1.27M
2.45%
-160.25K
-11.24%
Dec 31, 2025
Geode Capital Management, L.L.C.
1.25M
2.42%
-28.68K
-2.24%
Dec 31, 2025
Oak Hill Advisors, L.P.
1.11M
2.16%
--
--
Dec 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
AdvisorShares Insider Advantage ETF
0.97%
Royce Quant Small-Cap Quality Value ETF
0.41%
State Street SPDR S&P Biotech ETF
0.28%
Federated Hermes MDT Small Cap Core ETF
0.23%
Harbor Human Capital Factor US Small Cap ETF
0.19%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
Pacer US Small Cap Cash Cows ETF
0.16%
Invesco RAFI US 1500 Small-Mid ETF
0.15%
Avantis US Small Cap Value ETF
0.14%
iShares Micro-Cap ETF
0.13%
詳細を見る
AdvisorShares Insider Advantage ETF
比率0.97%
Royce Quant Small-Cap Quality Value ETF
比率0.41%
State Street SPDR S&P Biotech ETF
比率0.28%
Federated Hermes MDT Small Cap Core ETF
比率0.23%
Harbor Human Capital Factor US Small Cap ETF
比率0.19%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.18%
Pacer US Small Cap Cash Cows ETF
比率0.16%
Invesco RAFI US 1500 Small-Mid ETF
比率0.15%
Avantis US Small Cap Value ETF
比率0.14%
iShares Micro-Cap ETF
比率0.13%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
